

Purdue Sales and OxyContin Profit Contribution Summary

(\$000)

Year	OxyContin Net Sales	OxyContin Gross Sales	Total Purdue Gross Sales	OxyContin Gross Sales as a % of Total Gross Sales	OxyContin Profit Contribution After Tax
1995	3,185	3,385	251,190	1.3%	384
1996	46,388	48,929	312,133	15.7%	(265)
1997	127,603	144,827	411,972	35.2%	15,332
1998	268,635	301,233	601,230	50.1%	57,687
1999	539,873	612,155	900,660	68.0%	146,352
2000	936,672	1,067,380	1,327,928	80.4%	305,083
2001	1,175,355	1,379,084	1,674,676	82.3%	392,294
2002	1,225,552	1,460,933	1,710,661	85.4%	429,303
2003	1,579,184	1,975,093	2,102,659	93.9%	585,243
2004	1,294,519	1,667,561	1,794,829	92.9%	503,993
2005	943,375	1,188,406	1,285,214	92.5%	402,819
2006	595,309	660,908	755,663	87.5%	264,286

Notes

Gross Sales represents invoiced sales less credit memos issued by reason of rejections, defects, recalls or returns or because of retroactive price reductions, including but not limited to wholesaler chargebacks

Net Sales represents gross sales less early payment discounts, fees for services provided by wholesalers, price reductions or rebates provided to government authorities or managed care organizations, and management fees paid to group purchasing organizations.

After-Tax Product Contribution represents Net Sales less Cost Of Goods Sold, Shipping & Warehousing, Abbott Co-Promotion Fee, Sales & Promotional Expense, Fully allocated R&D Expense, Patient Assistance Program, Sales Force Allocation, and General & Administrative Expense less an assumed 43% tax rate